The reason for this may be that beneficial cardiac effects with etanercept early after MI is offset by its adverse cardiovascular effects such as potentiating platelet–monocyte aggregation and causing TNF-α imbalance in the long-term development of ischemic heart failure36, 37. The gene discussed is TNF; the disease is myocardial infarction.